HOME >> BIOLOGY >> NEWS
Clinical study reports findings of combination therapy with DOXIL

treatment regimen without compromising efficacy.

"This phase II study evaluated DVd as an alternative to the VAD regimen. With DVd, DOXIL is administered as a one hour infusion (compared to a 96 hour infusion with VAD, which also requires indwelling venous access), and vincristine as an IV push every 28 days. The results from this study are encouraging and further study of the DVd regimen in multiple myeloma is warranted," said Mohamad A. Hussein, M.D., Director of the Multiple Myeloma Research Program at the Cleveland Clinic Taussig Cancer Center, the lead investigator of the study.

About Multiple Myeloma and DOXIL
There are more than 14,600 new cases of myeloma in the U.S. each year, representing 20 percent of blood cancers and 1 percent of all types of cancer. Multiple myeloma is a cancer of plasma cells. Plasma cells are normally present in the bone marrow and are responsible for antibody production in response to infection and other immune triggering events. In myeloma, a defective plasma cell (myeloma cell) gives rise to the much larger number of myeloma cells which build up in the bone marrow. This process disrupts the normal immune system as well as displacing the normal bone marrow cells. 1

Indication
DOXIL is indicated for the treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinum-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment. DOXIL also is indicated for the treatment of AIDS-related Kaposi's sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy.

These indications are based on objective tumor response rates. No results are available from controlled trials that demonstrate a clinical benefit resulting from this treatment, suc
'"/>


8-May-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
9. Clinical trial shows timing of chemotherapy improves survival in breast cancer
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/12/2017)... , January 12, 2017 A new report by Allied ... that the global biometric technology market is expected to generate revenue of $10.72 billion ... Continue Reading ... Allied Market Research ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol Inc. ... Group, Inc., has been named to the elite "Forbes 30 Under ... one of 600 people in 20 fields nationwide to be recognized ... the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
(Date:1/6/2017)...  SomaLogic announced today that it has agreed ... iCarbonX, the China -based company ... Health Ecosystem that can define each person,s ,digital ... behavioral and psychological data, the Internet and artificial ... will provide proteomics data and applications expertise to ...
Breaking Biology News(10 mins):
(Date:1/13/2017)... ... January 13, 2017 , ... ... containing an organic compound called fulvic acid that farms, greenhouses and hydroponics operations ... grow cannabis are among the fastest growing segments of customers using this high ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... IS A SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful outcome ... expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with ...
(Date:1/12/2017)... ... ... Huffman Engineering, Inc. , a leader in control systems integration, today announced ... as a chemical engineer. In his new role, Beck will use his extensive ... manufacturing and water/wastewater industries. , Prior to joining Huffman Engineering, Beck served for nine ...
(Date:1/12/2017)... 2017   Protein Sciences Corporation , a ... Flublok Influenza Vaccine ®, announced today that its ... safety results and induced strong neutralizing antibodies against ... is expected to advance into human clinical trials ... Institute of Technology in Immunobiologicals of the Oswaldo ...
Breaking Biology Technology:
Cached News: